Aplagon

About Aplagon

Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapeutics for thromboinflammatory diseases, focusing on thrombotic and vascular occlusion-related cardiovascular conditions. Its lead asset, APAC, targets vascular injury with a triple-action mechanism comprising antiplatelet, anticoagulant, and anti-inflammatory effects to address a range of thromboinflammatory diseases. The company emphasizes research and development efforts across APAC therapeutic strategies and operates within the cardiovascular disease space. It is active in clinical development and has a全球